COLUMBUS, Ohio – Dr. Tanios Bekaii-Saab, medical director of gastrointestinal oncology at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James), has been selected to be a member of the editorial board for HemOnc Today, a bimonthly global publication that provides timely and authoritative reports on clinical issues, socioeconomic topics and industry developments and other relevant information for oncology and hematology professionals.
Bekaii-Saab specializes in experimental agents for gastrointestinal malignancies including pancreatic, liver and colon cancers. An associate professor of medicine in the OSUCCC-James and Pharmacology in Ohio State’s College of Medicine, he is a leader of the college’s disease specific research group for gastrointestinal oncology.
Bekaii-Saab leads an active clinical research program including a novel, two-arm randomized phase II pancreas cancer clinical trial at Ohio State’s Comprehensive Cancer Center that will study a formulation of the human reovirus, Reolysin that is designed to kill cancer cells.
Expected to enroll approximately 70 patients with pancreatic cancer, both at Ohio State and at other institutions, the study will compare the effects of two courses of treatment. One group of patients will receive the chemotherapy drugs carboplatin and paclitaxel. The other group will receive the two medications plus Reolysin, an engineered version of the human reovirus developed by Oncolytics Biotech Inc. of Calgary.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute
(NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 210-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top 20 cancer hospitals in the nation as ranked by U.S. News & World Report.
# # #
for a high-quality photograph of Dr. Tanios Bekaii-Saab.